1. Scrip

Adolescent Results Put Pfizer/BioNTech Ahead Of COVID Vaccine Pack, For Now

Hoping For EUA Before Start Of School Year

 
• By Alaric DeArment

An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.

Pfizer Inc. and BioNTech SE are positioned for the early lead in the broader market opportunity for vaccinating children against SARS-CoV-2, with strong results for their COVID-19 vaccine, BNT162b2, in adolescents aged 12-15. And if successful, another study in young children that just began dosing participants will fully round out the vaccine’s reach.

The companies said 31 March that topline results from their Phase III study in 2,260 adolescents showed a 100% protection rate and good tolerability

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

 
• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.